Panion & BF Biotech Inc - Asset Resilience Ratio
Panion & BF Biotech Inc (1760) has an Asset Resilience Ratio of -0.52% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 1760 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2021)
This chart shows how Panion & BF Biotech Inc's Asset Resilience Ratio has changed over time. See Panion & BF Biotech Inc shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Panion & BF Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Panion & BF Biotech Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$-16.14 Million | -0.52% |
| Total Liquid Assets | NT$-16.14 Million | -0.52% |
Asset Resilience Insights
- Limited Liquidity: Panion & BF Biotech Inc maintains only -0.52% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Panion & BF Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Panion & BF Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Panion & BF Biotech Inc (2009–2021)
The table below shows the annual Asset Resilience Ratio data for Panion & BF Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 2.36% | NT$69.79 Million ≈ $2.20 Million |
NT$2.95 Billion ≈ $93.04 Million |
-0.76pp |
| 2020-12-31 | 3.13% | NT$96.13 Million ≈ $3.03 Million |
NT$3.07 Billion ≈ $96.85 Million |
-2.12pp |
| 2019-12-31 | 5.25% | NT$100.32 Million ≈ $3.16 Million |
NT$1.91 Billion ≈ $60.25 Million |
+1.39pp |
| 2018-12-31 | 3.86% | NT$70.74 Million ≈ $2.23 Million |
NT$1.83 Billion ≈ $57.81 Million |
+2.53pp |
| 2017-12-31 | 1.32% | NT$16.49 Million ≈ $519.40K |
NT$1.25 Billion ≈ $39.30 Million |
-0.49pp |
| 2016-12-31 | 1.81% | NT$21.59 Million ≈ $680.14K |
NT$1.19 Billion ≈ $37.53 Million |
-0.25pp |
| 2015-12-31 | 2.06% | NT$24.24 Million ≈ $763.69K |
NT$1.18 Billion ≈ $37.03 Million |
-0.22pp |
| 2014-12-31 | 2.28% | NT$25.25 Million ≈ $795.54K |
NT$1.11 Billion ≈ $34.91 Million |
+1.37pp |
| 2013-12-31 | 0.91% | NT$9.10 Million ≈ $286.70K |
NT$1.00 Billion ≈ $31.52 Million |
-0.60pp |
| 2012-12-31 | 1.51% | NT$13.96 Million ≈ $439.69K |
NT$924.20 Million ≈ $29.12 Million |
-0.06pp |
| 2011-12-31 | 1.58% | NT$14.71 Million ≈ $463.51K |
NT$934.09 Million ≈ $29.43 Million |
+0.72pp |
| 2010-12-31 | 0.86% | NT$7.41 Million ≈ $233.46K |
NT$861.72 Million ≈ $27.15 Million |
-0.74pp |
| 2009-12-31 | 1.60% | NT$14.00 Million ≈ $441.20K |
NT$873.43 Million ≈ $27.52 Million |
-- |
About Panion & BF Biotech Inc
Panion & Bf Biotech Inc., a biotechnology pharmaceutical company, provides western medicines, cosmetics, testing reagents, food and chemical products in Taiwan, the United States, China, Hong Kong, Macau, and internationally. The company offers products in the areas of antibody, respiratory, gastrointestinal, COVID-19 IVD, antigen, anti-aging, active pharmaceutical ingredients, disease treatment,… Read more